Jan 25,2024 TOP STORY

Patient Risk Management Platform, Wave Health, Delivers Rare 93% Patient Compliance And 98% HCP Perceived Usefulness

Treatment Technologies & Insights (TTI) announced significant results from an eight-hospital, three-month study in Spain focusing on prostate cancer patients undergoing systemic therapy. In the PRO-WAVE1 study using the Wave Health App, patients engaged in a 13-week period completing a weekly symptom review (WSR). The study, accepted for presentation at the 2024 ASCO GU Symposium, revealed that care teams, comprising nurse coordinators and treating physicians, found the platform highly valuable, with 98% rating it useful. Additionally, 90% perceived a positive impact on communication, and 85% saw it addressing emerging patient issues. Among patients, 93% showed compliance, 93% were satisfied, and 84% accepted the app. Notably, a positive relationship was observed between app usage and emotional wellbeing, with active users experiencing a statistically significant increase. The study also uncovered progressing adverse events, emphasizing the platform's role in promptly identifying and addressing potential issues proactively.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jan 27,2024

A New Clinical Trial To Assess Holistic Lifestyle Digital Health Intervention with Women with Post-Gestational Diabetes

A new 4-year study (1-year randomized controlled trial with three years of follow-up) is registered on Clinicaltrials.gov to assess the efficacy of a digital intervention, which focuses on diet, physical activity, sleep and mental well-being, on the glucose regulation of 400 women who previously had gestational diabetes. Women from both intervention and control groups will be provided with an Oura ring for tracking physical activity, sleep, and heart rate variability (a proxy for stress), and the "HAPPY app," which will provide health promotion information about physical activity, diet, sleep, and mental wellbeing, as well as display the information collected (such as body mass index, blood pressure, and OGTT results). The active group will receive the "LVL UP app" a smartphone-based chatbot-delivered intervention, designed to provide personalized recommendations through multiple digital coaching sessions aimed at improving health literacy and practicing healthy lifestyles to prevent Type 2 diabetes and common mental disorders (i.e., anxiety, depression). The study is led by the Singapore Institute for Clinical Sciences (SICS) at the Agency for Science, Technology and Research, in collaboration with the National University of Singapore’s (NUS) Yong Loo Lin School of Medicine and the Singapore-ETH Centre.

CLINICAL STUDY

#mobile app

#coaching

View Analyst & Ambassador Comments
Go to original news
Jan 23,2024

AI Harnesses Tumor Genetics to Predict Treatment Response

Scientists at University of California San Diego School of Medicine leveraged a machine learning algorithm to tackle one of the biggest challenges facing cancer researchers: predicting when cancer will resist chemotherapy. The algorithm, trained on 718 genes commonly used in cancer genetic testing, successfully predicted responses to cisplatin in cervical cancer tumors. Unlike previous models, it considers broader biochemical networks crucial for cancer survival. The model's transparency in decision-making, identifying protein assemblies influencing treatment resistance, enhances trust and offers potential new targets for chemotherapy. The researchers believe the model has broad applications in improving current cancer treatment and pioneering new approaches.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jan 19,2024 TOP STORY

New RCT in cooperation with the UKE examines the effects of a holistic, digital therapy Levidex for MS

A new randomized controlled study, "Lamont" in collaboration with the University Medical Center Hamburg-Eppendorf (UKE), is investigating the effects of a holistic digital therapy called "levidex" on individuals with Multiple Sclerosis (MS). The online study focuses on assessing the impact of levidex across various stages and forms of MS, supporting patients in managing both physical and psychological MS-related issues, as well as optimizing their lifestyle. The study, led by Prof. Dr. Christoph Heesen, aims to compare levidex with standard care over six months. The digital intervention by GAIA aims to enhance the quality of life for MS patients by addressing lifestyle factors like nutrition, exercise, sleep quality, and mental well-being.

CLINICAL STUDY

#pdt

View Analyst & Ambassador Comments
Go to original news
Jan 23,2024

Smartphone Applications to Prevent type 2 Diabetes: a systematic review and meta-analysis

Evidence supporting the use of apps for lifestyle behavior change and diabetes prevention in people at high risk of diabetes is lacking. The aim of this systematic review was to determine the acceptability and effectiveness of smartphone applications (apps) for the prevention of type 2 diabetes. PubMed, Embase, CINAHL and PsychInfo were searched from 2008 to 2023. Included studies involved adults at high risk of developing diabetes evaluating an app intervention with the aim of preventing type 2 diabetes. Twenty-four studies (n=2378) were included in this systematic review, including nine randomized controlled trials (RCTs) with an average duration of 6 months, ten quasi-experimental and seven qualitative studies. Apps were effective at promoting weight loss and decreasing BMI, with no effect on glycated haemoglobin and waist circumference. The study concluded that smartphone apps have a promising effect on preventing type 2 diabetes by supporting weight loss. Future robust trials should include diverse populations in co-design and evaluation of apps and explore the role of artificial intelligence in further personalizing interventions for higher engagement and effectiveness.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jan 19,2024

‘Smart speaker’ shows potential for better self-management of Type 2 diabetes

Researchers from Stanford Medicine have created a voice-based artificial intelligence application that runs on a device already familiar to tens of millions of Americans: a “smart speaker,” commonly used to play music and check the weather. The app tells patients the correct insulin dose without requiring them to contact their doctor’s office or wait for an appointment. Participants in a randomized trial who used the system achieved optimal blood glucose levels far faster than the control group; they were also better about taking the prescribed amount of insulin at the time they were supposed to. The study followed 32 individuals with Type 2 diabetes who were all taking insulin and struggling to achieve healthy blood glucose levels. Half of those received a speaker preloaded with the voice-based artificial intelligence software created by the research team. Each participant’s insulin protocol — including starting insulin dose, fasting blood glucose range goal and insulin dose instructions — was included in the software on their device. At the end of the conversation, the software provided updated instructions by responding, for example, “OK, keep doing what you’re doing,” or “Up your dose” by a specified amount. The platform goes beyond remote monitoring by enabling remote patient intervention for the first time, the researchers said. Over the eight-week study period, 81% of patients in the group who used the app achieved glycemic control of their diabetes compared with 25% of patients who received traditional care. Patients in the trial managed by the AI had their insulin dose adjusted more frequently and needed far fewer doctor’s appointments to get their diabetes under control.

CLINICAL STUDY

#ai/software

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jan 25,2024

Assessment of Glycemic Control by Continuous Glucose Monitoring, Hemoglobin A1c, Fructosamine, and Glycated Albumin in Patients With End-Stage Kidney Disease and Burnt-Out Diabetes

Patients with diabetes and end-stage kidney disease (ESKD) may experience “burnt-out diabetes,” defined as having an HbA1c value <6.5% without antidiabetic therapy for >6 months. The research aims to assess glycemic control by continuous glucose monitoring (Dexcom G6 CGM) metrics and glycemic markers in ESKD patients on hemodialysis with burnt-out diabetes. In this pilot prospective study, glycemic control was assessed by continuous glucose monitoring (CGM), HbA1c measures, and glycated albumin and fructosamine measurements in patients with burnt-out diabetes (n = 20) and without a history of diabetes (n = 20). Patients with burnt-out diabetes had higher CGM-measured daily glucose levels, lower percent time in the range 70–180 mg/dL, higher percent time above range (>250 mg/dL), and longer duration of hyperglycemia >180 mg/dL (hours/day) compared with patients without diabetes. The use of CGM demonstrated that patients with burnt-out diabetes have significant undiagnosed hyperglycemia. CGM and glycated albumin provide better assessment of glycemic control than do values of HbA1c and fructosamine in patients with ESKD.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jan 17,2024 TOP STORY

Lunit INSIGHT CXR Excels in Long Nodule Detection - Exceptional Performance in Head-to-Head Study published in Radiology

The study led by a research team from Radboud University Medical Center, conducted a head-to-head validation of multiple commercial AI products from leading vendors, establishing Lunit INSIGHT CXR as the leading solution in the detection of lung nodules in chest X-rays. The study used radiographs from 386 patients, including 144 who had at least one nodule according to the reference standard CT image and were therefore considered true positive nodule cases; the remaining 242 were considered controls. 17 human readers, consisting of radiologists and radiology residents with varying experience levels, participated in the study. The mean AUC (Area Under the Curve) for human readers stood at 0.81, with a mean sensitivity of 71% and a mean specificity of 80%. Through the evaluation of seven commercially available CE-marked lung nodule detection algorithms on chest radiographs, Lunit INSIGHT CXR achieved the highest AUC (Area Under the Curve) of 0.93 in lung nodule detection, surpassing all other AI vendors and human readers (Mean AUC 0.81).

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Dec 28,2023

A Remotely Delivered, Semaglutide-Supported Specialist Weight Management Program: Preliminary Findings From a Retrospective Service Evaluation

Digital weight management interventions have the potential to increase access to novel pharmacotherapy for people living with obesity. At present, there is limited real-world evidence on the effectiveness, feasibility, and acceptability of this type of intervention. This retrospective service evaluation examines real-world data to evaluate the preliminary impact of Second Nature’s 24-month, remotely delivered, semaglutide-supported weight management intervention for adults living with obesity at 12 weeks. Retrospective data were extracted in October 2023 for participants who started the intervention between June 8, 2023, and July 22, 2023. The primary outcomes were weight change (kg) and percentage of weight change at 12 weeks. The secondary outcomes were the proportion of participants who achieved ?5% and ?10% weight loss and the feasibility and acceptability of this type of intervention. A total of 70.8% (n=80) of participants provided weight data at 12 weeks. The average weight loss observed over this 12-week period was 6.5 kg or 6.4% of their starting weight. Of the 80 participants who recorded weight readings, 62.5% (n=50) achieved ?5% weight loss, and 11.3% (n=9) achieved ?10% weight loss. This retrospective preliminary service evaluation suggests that a remotely delivered semaglutide-supported weight management intervention has the potential to be effective, feasible, and acceptable for self-paying consumer adults with obesity in the United Kingdom.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jan 17,2024 TOP STORY

Better Therapeutics Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx is More Effective and Less Costly than Standard of Care Alone

Better Therapeutics announced the publication of health economic data for its prescription-only digital behavioral treatment for type 2 diabetes (T2D), AspyreRx. The study, titled "Cost-Effectiveness Analysis of a Prescription Digital Therapeutic in Type 2 Diabetes'' has been published in Advances in Therapy peer-reviewed medical journal. This latest study modeled the cost-effectiveness of AspyreRx plus standard of care (SoC) versus SoC alone in T2D over a lifetime horizon. From a healthcare payer perspective, AspyreRx plus SoC versus SoC alone was dominant because AspyreRx was associated both with gains in quality-adjusted life years (QALYs) and cost savings of $7,343 per patient over the lifetime horizon. AspyreRx plus SoC was cost-effective at a willingness-to-pay of $100,000 per QALY over SoC alone, with an incremental net monetary benefit (INMB) of $17,443. At other commonly applied thresholds of $50,000 and $150,000 per QALY, the study yielded INMBs of $12,393 and $22,493, respectively. Savings were primarily driven by a reduction in drug costs, followed by reductions in adverse event costs.

CLINICAL STUDY

#pdt

View Analyst & Ambassador Comments
Go to original news
Subscribe to CLINICAL STUDY